We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRU icon
601
Prudential Financial
PRU
$42.6B
– –
-4,521
Closed -$530K
PSMT icon
602
Pricesmart
PSMT
$5.94B
– –
-11,504
Closed -$934K
PYPL icon
603
PayPal
PYPL
$50.3B
– –
-4,307
Closed -$250K
QLYS icon
604
Qualys
QLYS
$4.76B
– –
-3,214
Closed -$458K
QTRX icon
605
Quanterix
QTRX
$159M
– –
-21,461
Closed -$284K
REPL icon
606
Replimune Group
REPL
$454M
– –
-29,300
Closed -$264K
RITM icon
607
Rithm Capital
RITM
$5.58B
– –
-14,200
Closed -$155K
RLAY icon
608
Relay Therapeutics
RLAY
$4B
– –
-46,702
Closed -$304K
RVTY icon
609
Revvity
RVTY
$12.6B
– –
-12,058
Closed -$1.26M
RXST icon
610
RxSight
RXST
$254M
– –
-8,942
Closed -$538K
SD icon
611
SandRidge Energy
SD
$503M
– –
-41,580
Closed -$538K
SDGR icon
612
Schrodinger
SDGR
$1.13B
– –
-16,428
Closed -$318K
SEDG icon
613
SolarEdge
SEDG
$2.37B
– –
-26,824
Closed -$678K
SIBN icon
614
SI-BONE Inc
SIBN
$818M
– –
-11,691
Closed -$151K
SITM icon
615
SiTime
SITM
$13.8B
– –
-6,587
Closed -$819K
SKIN icon
616
SkinHealth Systems
SKIN
$83.4M
– –
-59,133
Closed -$114K
SLDB icon
617
Solid Biosciences
SLDB
$792M
– –
-1,743,398
Closed -$9.89M
SLP icon
618
Simulations Plus
SLP
$371M
– –
-16,674
Closed -$811K
SLRC icon
619
SLR Investment Corp
SLRC
$704M
– –
-23,119
Closed -$372K
SNOW icon
620
Snowflake
SNOW
$98.1B
– –
-8,383
Closed -$1.13M
SON icon
621
Sonoco
SON
$5.83B
– –
-14,314
Closed -$726K
SPGI icon
622
S&P Global
SPGI
$124B
– –
-817
Closed -$364K
SRI icon
623
Stoneridge
SRI
$200M
– –
-29,592
Closed -$472K
STAA icon
624
STAAR Surgical
STAA
$1.19B
– –
-8,895
Closed -$423K
TALK icon
625
Talkspace
TALK
$874M
– –
-88,712
Closed -$204K
23 24
25
26 27

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.